Rituximab therapy in severe connective tissue disease- associated interstitial lung disease: A retrospective single-centre observational study

<b>What the study adds.</b> Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a challenging clinical entity. Rituximab (RTX), a chimeric monoclonal antibody targeted to CD20+ B cells, resulting in B-cell depletion, has been suggested as a potential therapeutic modality in refractory or severe disease. A single-centre experience of RTX salvage therapy in progressive CTD-ILD is presented.<b>Implications of the findings.</b> This small study suggests a possible role for RTX therapy in severe or refractory CTD-ILD.